EXTENSIVE STAGE SMALL CELL LUNG CANCER
Clinical trials for EXTENSIVE STAGE SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
Promising new combo for tough lung cancer: Low-Dose radiation plus immunotherapy
Disease control Not yet recruitingThis study tests a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. It combines low-dose radiation to the chest with an immunotherapy drug (adebrelimab) and chemotherapy, followed by maintenance immunotherapy for up to t…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jiangmen Central Hospital • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New hope for tough lung cancer: combo therapy enters phase II trial
Disease control Not yet recruitingThis study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants mus…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New drug duo takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new combination of two drugs, risvutatug rezetecan and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find safe dose levels, check for side effects, and see if the combination can shrink tumors. T…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New combo aims to fight tough lung cancer after first treatment fails
Disease control Not yet recruitingThis study tests whether adding a drug called lurbinectedin to standard chemotherapy (paclitaxel) works better than paclitaxel alone for people with advanced small cell lung cancer that has gotten worse after initial treatment. About 69 adults will be randomly assigned to one of …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
New drug cocktail aims to stall aggressive lung cancer
Disease control Not yet recruitingThis study tests whether combining two drugs—lurbinectedin and durvalumab—can help keep extensive-stage small-cell lung cancer from progressing after initial treatment. About 50 adults whose cancer did not worsen after standard chemo-immunotherapy will receive the combo as mainte…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New hope for tough lung cancer: drug combo targets tumors after first treatment fails
Disease control Not yet recruitingThis study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in 30 people with extensive-stage small cell lung cancer whose disease got worse after initial chemotherapy plus immunotherapy. The goal is to see if the combo can shrink tumors or slow cancer gro…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: China Medical University, China • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
Engineered immune cells take aim at deadliest lung cancer
Disease control Not yet recruitingThis early-phase study tests a personalized cell therapy for people with extensive-stage small cell lung cancer or similar neuroendocrine cancers that came back after standard treatment. Researchers take a patient's own immune cells, modify them to recognize a protein called B7-H…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for aggressive lung cancer: drug duo takes on chemo in major trial
Disease control Not yet recruitingThis study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New study tracks how lung cancer patients are really treated
Knowledge-focused Not yet recruitingThis study will observe 96 adults with extensive-stage small cell lung cancer to see how they are treated in real-world hospital settings and how they respond. No experimental treatments are given; doctors choose standard therapies as usual. Researchers will collect data from med…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:59 UTC